

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of fosinopril or a pharmaceutically acceptable salt thereof to prepare a medicament for reducing the risk of occurrence of a cardiovascular event in a dialysis patient.
2. (Original) Use according to Claim 1, in which the cardiovascular event is a cardiac insufficiency.
3. (Original) Use according to Claim 2, in which the cardiovascular event is a cardiac insufficiency decompensation.
4. (Original) Use according to Claim 1, in which the cardiovascular event is a myocardial infarction.
5. (Original) Use according to Claim 1, in which the cardiovascular event is an angina.
6. (Original) Use according to Claim 1, in which the cardiovascular event is a stroke.
7. (Original) Use according to Claim 1, in which the cardiovascular event is a non-fatal cardiac arrest.
8. (Original) Use according to Claim 1, in which the cardiovascular event is a death of cardiovascular origin.
9. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 8~~, in which the patient is a blood dialysis patient.
10. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 8~~, in which the dialysis patient presents left-ventricular hypertrophy.
11. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 10~~, in which the patient undergoes a dialysis treatment on account of a chronic kidney disease in the terminal phase.
12. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 11~~, in which the patient has been undergoing a dialysis treatment for at least six months.

13. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 12~~, in which the patient undergoes a dialysis session at least three times a week.

14. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 13~~, in which the patient is a man or a woman 50 to 80 years old.

15. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 14~~, in which the fosinopril is in the form of fosinopril sodium.

16. (Currently Amended) Use according to claim 1 ~~one of Claims 1 to 15~~, in which the medicament is intended for oral administration.

17. (Original) Use according to Claim 16, in which the medicament comprises from 5 to 20 mg of fosinopril or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) Use according to Claim 16 ~~or 17~~, in which the medicament is intended for a daily administration of about 0.01 mg/kg to about 25 mg/kg of fosinopril or a pharmaceutically acceptable salt thereof.

19. (Original) Use according to Claim 18, in which the medicament is intended for a daily administration of about 10 mg of fosinopril or a pharmaceutically acceptable salt thereof.